JASCAYD

• drugnerandomilast12 co-mentions · 3 sources
• tagApproval12 co-mentions · 3 sources
• companyBoehringer Ingelheim Corp6 co-mentions · 3 sources
• tagSmall Molecule6 co-mentions · 3 sources

Trials studying JASCAYD

• phase3A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseasesrecruitingn=400
• phase3A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosisrecruitingn=80
• phase3A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)not yet recruitingn=35
• phase3A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosisnot yet recruitingn=448
• phase3FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progressionnot yet recruitingn=466
• phase3A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilastrecruitingn=1,700
• phase2Platform Clinical Study for Conquering Sclerodermarecruitingn=400
• phase1A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Foodcompletedn=15